Biothera Pharmaceuticals to Present at the Sachs Associates 2nd Annual Immuno-Oncology BD&L and Investment Forum

EAGAN, MN — May 31, 2016 — Biothera Pharmaceuticals, Inc. today announced that Chief Executive Officer Barry Labinger will present at the Sachs Associates 2nd Annual Immuno-Oncology BD&L and Investment Forum on Friday, June 3, 2016 at 2:30 p.m. Central Time in Chicago.

Mr. Labinger will provide an overview of Biothera and its clinical development plans in oncology, which include the initiation of three Phase 2 studies this year to evaluate the combination of company’s developmental immunotherapeutic and checkpoint inhibitors in NSCLC, metastatic melanoma and gastric cancer.

About Biothera Pharmaceuticals, Inc.
Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a first-in-class, mid-clinical stage cancer immunotherapy that orchestrates an integrated anti-cancer immune response in combination with checkpoint inhibitors and tumor-targeting and anti-angiogenesis monoclonal antibodies. Imprime PGG has been well-tolerated in trials in over 400 subjects and has established proof of concept in multiple clinical studies, including single-arm and randomized phase 2 studies in non-small cell lung cancer (NSCLC), colorectal cancer, and chronic lymphocytic leukemia.

Contact:
David Walsh
SVP Communications
Biothera Pharmaceuticals, Inc.
651-256-4606
dwalsh@biothera.com

 

###

Share

David Walsh

Leave a Reply

Your email address will not be published. Required fields are marked *